A new type of treatment for osteoarthritis, currently in canine clinical trials, shows promise for eventual use in humans.
The treatment, developed by Cornell biomedical engineers, is a synthetic version of a naturally occurring joint lubricant that binds to the surface of cartilage in joints and acts as a cushion during high-impact activities, such as running.
“When the production of that specific lubricant goes down, it creates higher contact between the surfaces of the joint and, over time, it leads to osteoarthritis,” said David Putnam, a professor in the College of Engineering with appointments in the Meinig School of Biomedical Engineering and the Smith School of Chemical and Biomolecular Engineering.
Putnam is senior author of “Boundary Mode Lubrication of Articular Cartilage With a Biomimetic Diblock Copolymer,” published June 4 in Proceedings of the National Academy of Sciences, USA. Zhexun Sun, a postdoctoral researcher in Putnam’s lab, is the paper’s first author.
The study focuses on a naturally occurring joint lubricant called lubricin, the production of which declines following traumatic injuries to a joint, such as a ligament tear in a knee.
The knee is lubricated in two ways – hydrodynamic mode and boundary mode.
Hydrodynamic mode lubrication occurs when the joint is moving fast and there isn’t a strong force pushing down on it. In this mode, joints are lubricated by compounds like hyaluronic acid (HA) that are thick and gooey, like car oil. There are numerous HA products on the market, approved by the Food and Drug Administration, for treating hydrodynamic mode lubrication disorders.
But HA is ineffective when strong forces are pushing down on the joint, such as those that occur during running or jumping. In these instances, thick gooey HA squirts out from between the cartilage surfaces, and boundary mode lubrication is necessary. Under these forces, lubricin binds to the surface of the cartilage. It contains sugars that hold on to water, to cushion hard forces on the knee.
In the paper, the researchers describe a synthetic polymer they developed that mimics the function of lubricin and is much easier to produce. “We are in clinical trials, with dogs that have osteoarthritis, with our collaborators at Cornell’s College of Veterinary Medicine,” Putnam said.
Those collaborators – Ursula Krotscheck and Kei Hayashi, both associate professors in the Section of Small Animal Surgery in the Department of Clinical Sciences – use a force plate to measure the efficacy of the treatments. The force plate quantifies the amount of force that a dog exerts with each paw, to measure whether they are favoring one paw over another.
“Once we finalize the efficacy study in dogs, we will be in a very good position to market the material for veterinary osteoarthritis treatment,” Putnam said. From there, the human market for a lubricin substitute should follow, just as HA has been made available for human use, mainly in knees.
The Latest on: Osteoarthritis
via Google News
The Latest on: Osteoarthritis
- Tips for Exercising When You Have Osteoarthritison December 6, 2019 at 10:30 am
That's why it's critical to take a smart, measured approach to exercise if you're one of the more than 30 million Americans that has osteoarthritis, according to the Centers for Disease Control and ...
- Subchondral bone lesions may be clinically important, treatable with bone substituteon December 6, 2019 at 5:53 am
Subchondroplasty, an arthroscopic procedure to inject a bone substitute material into chronic bone marrow lesions, may yield clinically significant and durable improvement in pain among patients with ...
- Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Numberon December 4, 2019 at 4:11 pm
ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III ...
- Exercises for Osteoarthritison December 3, 2019 at 10:49 am
Osteoarthritis is the most common type of arthritis, affecting 31 million people in the U.S., says Marcy O'Koon, senior director, consumer health, Arthritis Foundation. The degenerative joint disease ...
- 'The pain is bad and can be daily': Kris Smith shares the workout he uses to help with his osteoarthritis after opening a new gym in Melbourneon December 3, 2019 at 6:59 am
For 15 years I've needed two full knee replacements,' he wrote. 'I have bad osteoarthritis and the pain is bad and can be daily, but apparently I'm still too young... but is that stopping me? NO!' The ...
- Osteoarthritis Treatment Market To Grow At A CAGR of 7.6% Till 2023|Industry Growth Analysis By Size, Share and Revenueon December 3, 2019 at 1:49 am
Dec 03, 2019 (AmericaNewsHour) -- Osteoarthritis is a long-term chronic disease which occurs due to deterioration of cartilaginous muscles in joints and increases pain and stiffness in bone joint in ...
- OSU researcher makes breakthrough toward finding osteoarthritis therapieson December 2, 2019 at 8:17 am
Researchers at Oregon State University are one step closer to curbing osteoarthritis after making a breakthrough by providing the first ever complete look at what's happening to joints with the ...
- Arthritis Research Canada - Preventing Knee Osteoarthritis In Youth Who Play Sportson November 27, 2019 at 11:06 am
Millions of Canadians currently live with the pain and disability of osteoarthritis (OA), a disabling joint condition. It is estimated that by 2040, 25% of all Canadians will have OA. This percentage ...
- Global Osteoarthritis Treatment Market Expected to Flourish at a Significant CAGR of 7.6% By 2027on November 26, 2019 at 3:58 am
Nov 26, 2019 (AmericaNewsHour) -- The global osteoarthritis treatment market is segmented into medications such as acetaminophen and non-steroidal anti-inflammatory. Among these segments, ...
- Sr/PTA Metal Organic Framework as A Drug Delivery System for Osteoarthritis Treatmenton November 26, 2019 at 3:03 am
A Sr-based metal-organic framework (MOF) is introduced as ketoprofen carrier to form a comprehensive system for treating osteoarthritis (OA), and the drug loading amount and release rate is ...
via Bing News